Sofosbuvir/ledipasvir/ribavirin cures 100% of genotype 1 hepatitis C patients

Edward Gane presenting at CROI 2013. © Liz Highleyman /
Published: 05 March 2013

An interferon-free regimen containing sofosbuvir (formerly GS-7997), ledipasvir (formerly GS-5885) and ribavirin produced a 12-week post-treatment sustained virological response (SVR12) rate of 100% for both treatment-naive hepatitis C patients and prior interferon non-responders, according to data presented yesterday at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.

Direct-acting antiviral agents that target different steps of the hepatitis C virus lifecycle have ushered in a new era of treatment, but many patients and clinicians are awaiting all-oral therapy that avoids interferon and its difficult side-effects.

Edward Gane from Auckland Clinical Studies presented the latest data from the ELECTRON trial, sponsored by Gilead Sciences.

"Adding ledipasvir increased the efficacy of sofosbuvir plus ribavirin".

ELECTRON investigators initially tested a simple 12-week regimen of the once-daily nucleotide analogue HCV polymerase inhibitor sofosbuvir plus 1000-1200mg weight-based ribavirin for previously untreated people with easier-to-treat HCV genotypes 2 or 3. As reported at the 2011 AASLD Liver Meeting, that regimen cured 100% of these patients.

The ELECTRON researchers then looked at genotype 1 patients, both treatment-naive and null responders to previous interferon-based therapy. As Gane reported at CROI last year, sofosbuvir/ribavirin alone was not adequate for this harder-to-treat population. While participants saw a rapid decline in HCV RNA and had undetectable viral load at the end of therapy, some treatment-naive patients and almost all prior null responders relapsed, resulting in cure rates of 84% and 10%, respectively.

The investigators then asked whether adding a second direct-acting agent – the NS5A replication complex inhibitor ledipasvir – could increase cure rates for people with HCV genotype 1. Studies to date have shown that drugs in this class are highly potent and well tolerated.

The analysis included 25 treatment-naive participants and nine prior null responders. Two-thirds of the naive participants were women, whilst 78% of the experienced patients were men. Overall, about 90% were white and the average age was 48 years. Most had unfavourable IL28B gene patterns (only one-third of the treatment-naive and none of the experienced patients had the favourable CC pattern associated with good interferon response). More than 80% had the more difficult-to-treat HCV subtype 1a and baseline HCV RNA levels were high.

After four weeks on treatment, all treatment-naive patients and all but one null responder had rapid virological response and reached undetectable HCV RNA. By the end of the 12-week course of therapy, the remaining null responder also achieved viral suppression, yielding end-of-treatment response rates of 100% for both groups. At both 4 and 12 weeks post-treatment, all participants in both groups maintained undetectable HCV viral load and achieved SVR12, considered a cure.

The triple combination regimen was generally safe and well-tolerated. Two people (8%) experienced serious adverse events and one person (4%) stopped treatment for this reason. The most common side-effects were anaemia (20%), depression (8%) and headache (4%). About 44% experienced grade 3 laboratory abnormalities including anaemia.

Based on these findings the ELECTRON researchers concluded, "Adding ledipasvir increased the efficacy of sofosbuvir plus ribavirin".

Gilead is currently testing a fixed-dose coformulation containing sofosbuvir and ledipasvir in a phase III trial. Investigators will also look at a dual combination of sofosbuvir plus ledipasvir without ribavirin, as adding ledipasvir lowers the risk of relapse and may make ribavirin unnecessary for some or all patients.


Gane E et al. ELECTRON: 100% suppression of viral load through 4 weeks’ post-treatment for sofosbuvir + ledipasvir (GS-5885) + ribavirin for 12 weeks in treatment-naive and -experienced hepatitis C virus GT 1 patients. 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, abstract 41LB, 2013.

View abstract 41LB on the conference website.

A webcast of the session in which this research was presented, Advances in hepatitis therapy, is available on the conference website.

Hepatitis information

For more information on hepatitis visit

Infohep is a project we're working on with the World Hepatitis Alliance and the European Liver Patients Association.

Visit >

NAM is partnering with gTt (Barcelona), GAT (Lisbon) and LILA (Como) to deliver the CROI 2013 bulletins, which have also been made possible thanks to support from Bristol-Myers Squibb. NAM’s wider conference news reporting services have been supported by Abbott, Boehringer Ingelheim, Janssen, Roche and ViiV Healthcare. The funders have no editorial control over the content of the materials.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.